vs
HERON THERAPEUTICS, INC.（HRTX）与READING INTERNATIONAL INC（RDI）财务数据对比。点击上方公司名可切换其他公司
READING INTERNATIONAL INC的季度营收约是HERON THERAPEUTICS, INC.的1.2倍（$50.3M vs $40.6M），READING INTERNATIONAL INC净利率更高（-5.1% vs -7.3%，领先2.2%），HERON THERAPEUTICS, INC.同比增速更快（-0.5% vs -14.2%），过去两年HERON THERAPEUTICS, INC.的营收复合增速更高（8.2% vs 5.6%）
安提贝制药是一家总部位于多伦多的制药企业，由曾参与创立全球首个气态介质药物开发企业NicOx的约翰·L·华莱士创立于2009年。该企业专注于依托气态介质技术研发缓解疼痛与炎症的药物，2013年在多伦多风险交易所挂牌，2015年收购再生医学领域经销商Citagenix，2020年11月转板多伦多证券交易所。
雷丁公司是总部位于美国费城的铁路企业，1924年起在宾夕法尼亚州东部及周边各州提供客运与货运运输服务，直至1976年被联合铁路公司收购。
HRTX vs RDI — 直观对比
营收规模更大
RDI
是对方的1.2倍
$40.6M
营收增速更快
HRTX
高出13.7%
-14.2%
净利率更高
RDI
高出2.2%
-7.3%
两年增速更快
HRTX
近两年复合增速
5.6%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $40.6M | $50.3M |
| 净利润 | $-3.0M | $-2.6M |
| 毛利率 | 72.6% | — |
| 营业利润率 | 0.1% | -1.9% |
| 净利率 | -7.3% | -5.1% |
| 营收同比 | -0.5% | -14.2% |
| 净利润同比 | -180.6% | -14.5% |
| 每股收益（稀释后） | $-0.01 | $-0.11 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收HRTXRDI
| Q4 25 | $40.6M | $50.3M | ||
| Q3 25 | $38.2M | $52.2M | ||
| Q2 25 | $37.2M | $60.4M | ||
| Q1 25 | $38.9M | $40.2M | ||
| Q4 24 | $40.8M | $58.6M | ||
| Q3 24 | $32.8M | $60.1M | ||
| Q2 24 | $36.0M | $46.8M | ||
| Q1 24 | $34.7M | $45.1M |
净利润HRTXRDI
| Q4 25 | $-3.0M | $-2.6M | ||
| Q3 25 | $-17.5M | $-4.2M | ||
| Q2 25 | $-2.4M | $-2.7M | ||
| Q1 25 | $2.6M | $-4.8M | ||
| Q4 24 | $3.7M | $-2.2M | ||
| Q3 24 | $-4.8M | $-7.0M | ||
| Q2 24 | $-9.2M | $-12.8M | ||
| Q1 24 | $-3.2M | $-13.2M |
毛利率HRTXRDI
| Q4 25 | 72.6% | — | ||
| Q3 25 | 68.8% | — | ||
| Q2 25 | 73.5% | — | ||
| Q1 25 | 78.3% | — | ||
| Q4 24 | 74.9% | — | ||
| Q3 24 | 71.2% | — | ||
| Q2 24 | 70.8% | — | ||
| Q1 24 | 75.6% | — |
营业利润率HRTXRDI
| Q4 25 | 0.1% | -1.9% | ||
| Q3 25 | -10.7% | -0.6% | ||
| Q2 25 | -4.4% | 4.8% | ||
| Q1 25 | 8.1% | -17.2% | ||
| Q4 24 | 10.2% | 2.6% | ||
| Q3 24 | -13.6% | -0.6% | ||
| Q2 24 | -17.9% | -16.4% | ||
| Q1 24 | -13.8% | -16.7% |
净利率HRTXRDI
| Q4 25 | -7.3% | -5.1% | ||
| Q3 25 | -45.8% | -8.0% | ||
| Q2 25 | -6.4% | -4.4% | ||
| Q1 25 | 6.8% | -11.8% | ||
| Q4 24 | 9.0% | -3.8% | ||
| Q3 24 | -14.8% | -11.7% | ||
| Q2 24 | -25.6% | -27.4% | ||
| Q1 24 | -9.1% | -29.4% |
每股收益（稀释后）HRTXRDI
| Q4 25 | $-0.01 | $-0.11 | ||
| Q3 25 | $-0.10 | $-0.18 | ||
| Q2 25 | $-0.02 | $-0.12 | ||
| Q1 25 | $0.01 | $-0.21 | ||
| Q4 24 | $0.02 | $-0.11 | ||
| Q3 24 | $-0.03 | $-0.31 | ||
| Q2 24 | $-0.06 | $-0.57 | ||
| Q1 24 | $-0.02 | $-0.59 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $28.6M | $10.5M |
| 总债务越低越好 | — | $185.1M |
| 股东权益账面价值 | $14.3M | $-18.2M |
| 总资产 | $255.9M | $434.9M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资HRTXRDI
| Q4 25 | $28.6M | $10.5M | ||
| Q3 25 | $43.1M | $8.1M | ||
| Q2 25 | $16.5M | $9.1M | ||
| Q1 25 | $19.3M | $5.9M | ||
| Q4 24 | $25.8M | $12.4M | ||
| Q3 24 | $25.7M | $10.1M | ||
| Q2 24 | $18.4M | $9.3M | ||
| Q1 24 | $20.4M | $7.5M |
总债务HRTXRDI
| Q4 25 | — | $185.1M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $202.7M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益HRTXRDI
| Q4 25 | $14.3M | $-18.2M | ||
| Q3 25 | $14.9M | $-12.1M | ||
| Q2 25 | $-27.3M | $-7.7M | ||
| Q1 25 | $-28.5M | $-8.1M | ||
| Q4 24 | $-33.7M | $-4.4M | ||
| Q3 24 | $-40.0M | $1.6M | ||
| Q2 24 | $-37.9M | $6.5M | ||
| Q1 24 | $-33.8M | $18.0M |
总资产HRTXRDI
| Q4 25 | $255.9M | $434.9M | ||
| Q3 25 | $248.9M | $435.2M | ||
| Q2 25 | $232.1M | $438.1M | ||
| Q1 25 | $235.8M | $441.0M | ||
| Q4 24 | $233.1M | $471.0M | ||
| Q3 24 | $220.8M | $495.7M | ||
| Q2 24 | $218.1M | $494.9M | ||
| Q1 24 | $217.9M | $494.9M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-9.2M | $4.3M |
| 自由现金流经营现金流 - 资本支出 | — | $4.1M |
| 自由现金流率自由现金流/营收 | — | 8.2% |
| 资本支出强度资本支出/营收 | 0.0% | 0.3% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-2.9M |
8季度趋势，按日历期对齐
经营现金流HRTXRDI
| Q4 25 | $-9.2M | $4.3M | ||
| Q3 25 | $1.3M | $295.0K | ||
| Q2 25 | $-10.9M | $1.6M | ||
| Q1 25 | $-8.9M | $-7.7M | ||
| Q4 24 | $-11.8M | $8.0M | ||
| Q3 24 | $3.4M | $1.3M | ||
| Q2 24 | $-4.6M | $-10.4M | ||
| Q1 24 | $-9.5M | $-2.8M |
自由现金流HRTXRDI
| Q4 25 | — | $4.1M | ||
| Q3 25 | — | $-246.0K | ||
| Q2 25 | $-11.1M | $1.2M | ||
| Q1 25 | $-9.0M | $-8.0M | ||
| Q4 24 | — | $7.0M | ||
| Q3 24 | $2.9M | $-1.1M | ||
| Q2 24 | — | $-10.6M | ||
| Q1 24 | — | $-4.7M |
自由现金流率HRTXRDI
| Q4 25 | — | 8.2% | ||
| Q3 25 | — | -0.5% | ||
| Q2 25 | -29.8% | 1.9% | ||
| Q1 25 | -23.1% | -19.8% | ||
| Q4 24 | — | 12.0% | ||
| Q3 24 | 9.0% | -1.8% | ||
| Q2 24 | — | -22.7% | ||
| Q1 24 | — | -10.4% |
资本支出强度HRTXRDI
| Q4 25 | 0.0% | 0.3% | ||
| Q3 25 | 0.0% | 1.0% | ||
| Q2 25 | 0.6% | 0.6% | ||
| Q1 25 | 0.3% | 0.6% | ||
| Q4 24 | — | 1.7% | ||
| Q3 24 | 1.3% | 4.0% | ||
| Q2 24 | — | 0.5% | ||
| Q1 24 | — | 4.3% |
现金转化率HRTXRDI
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | -3.37× | — | ||
| Q4 24 | -3.22× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
HRTX
| CINVANTI | $22.9M | 56% |
| ZYNRELEF | $12.5M | 31% |
| Aponvie | $3.8M | 9% |
| SUSTOL | $1.3M | 3% |
RDI
| Cinema Exhibition Segment | $46.9M | 93% |
| Real Estate Revenue | $3.4M | 7% |
